Specifically, we observed a significant decrease in the levels of MIP-1α, GM-CSF, IL-13, IL-6, IL-10, IL-5, IL-12p70, and IL-4 after SNS administration, all of which are associated with the severity of MMD symptoms and cancer prognosis. The gene discussed is IL5; the disease is multiminicore myopathy.